Loading news...
ELTP reports surging revenue and profit in third-quarter fiscal 2026, but margin pressure and M&A ambitions steal the spotlight.
Elite Pharmaceuticals, Inc. (ELTP) Q3 2026 Earnings Call Prepared Remarks Transcript
Conference Call Scheduled for Wednesday, February 18 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - February 17, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the third quarter of fiscal year 2026, the three months ended December 31, 2025 ("Third Quarter"). Consolidated revenues for the three-month period ending December 31, 2025, were $31.6 million, an increase of $17.2 million or approximately 120% as compared to the comparable period of the prior fiscal year.
Financials for Third Quarter of Fiscal Year 2026 Ended December 31, 2025 will be released on Tuesday, February 17, 2026 Northvale, New Jersey--(Newsfile Corp. - February 11, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the third quarter financial results of the 2026 fiscal year will be released on Tuesday, February 17, 2026. Elite's management will host a live conference call on Wednesday, February 18th, at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update.
Elite Pharmaceuticals delivers record second-quarter fiscal 2026 earnings as lisdexamfetamine sales surged, though margins faced competitive pressure.
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q2 2026 Earnings Call November 17, 2025 11:30 AM EST Company Participants Nasrat Hakim - Chairman, CEO & President Carter Ward - CFO, Secretary & Treasurer Presentation Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Second Quarter of Fiscal Year 2026 Conference Call. [Operator Instructions] Before management begins speaking, the conference has the following statement.
Conference Call Scheduled for Monday, November 17 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - November 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the second quarter of fiscal year 2026 ended September 30, 2025 ("Second Quarter"). Consolidated revenues for the three-month period ending September 30, 2025, were $36.3 million, an increase of $17.4 million or approximately 92% as compared to the comparable period of the prior fiscal year.
Financials for Second Quarter of Fiscal Year 2026 Ended September 30, 2025 will be released on Friday, November 14, 2025 Northvale, New Jersey--(Newsfile Corp. - November 10, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2026 fiscal year will be released on Friday, November 14, 2025. Elite's management will host a live conference call on Monday, November 17th, at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update.
Elite Pharmaceuticals reports strong first-quarter fiscal 2026 results with rising direct sales, higher-margin products and expanding gross profit.
Conference Call Scheduled for Friday, August 15 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - August 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2026 ended June 30, 2025 ("First Quarter"). Consolidated revenues for the three-month period ending June 30, 2025, were $40.2 million, an increase of $21.4 million or approximately 114% as compared to the comparable period of the prior fiscal year.
ELTP and TSSI are growth stories with recent material pull-backs.
Financials for First Quarter of Fiscal Year 2026 Ended June 30, 2025 will be released on Thursday, August 14, 2025 Northvale, New Jersey--(Newsfile Corp. - August 8, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2026 fiscal year will be released on Thursday, August 14, 2025. Elite's management will host a live conference call on Friday, August 15th, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update.
ELTP posts record fiscal 2025 revenues and operating income gains, fueled by new launches and expanding generics market share.
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q4 2025 Earnings Conference Call July 1, 2025 11:30 AM ET Company Participants Carter J. Ward - CFO, Secretary & Treasurer Nasrat Hakim - Chairman, CEO & President Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Conference Call.
Conference Call Scheduled for Tuesday, July 1 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - June 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2025 ("Fiscal 2025"). Consolidated revenues for Fiscal 2025 were $84.0 million, an increase of $27.4 million or approximately 48% as compared to the comparable period of the prior fiscal year.
Financials for Fiscal Year 2025 Ended March 31, 2025 will be released on Monday, June 30, 2025 Northvale, Northvale, New Jersey--(Newsfile Corp. - June 23, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that it would release its 2025 year-end financial results on Monday, June 30, 2025. Elite's management will host a live conference call on Tuesday, July 1st, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update.
Northvale, New Jersey--(Newsfile Corp. - June 16, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today reported positive results from a pivotal bioequivalence study for an undisclosed anticoagulant generic drug product. IQVIA reported branded product sales for the twelve months ending April 2025 of $27 billion.
Northvale, New Jersey--(Newsfile Corp. - April 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Percocet® (oxycodone hydrochloride and acetaminophen tablets, USP CII) 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets. Oxycodone HCl and acetaminophen is indicated for the relief of moderate to moderately severe pain.
Northvale, New Jersey--(Newsfile Corp. - March 3, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today the shipment of its first lot of finished product from its new FDA-approved expanded campus. The new facility, located at 144 Ludlow Avenue in Northvale, New Jersey, includes packaging, inventory and warehouse space.
Elite Pharmaceuticals' third-quarter fiscal 2025 reports a revenue drop and a net loss. However, delayed shipments impact results.